Rescue Tocilizumab in MOGAD Optic Neuritis Refractory to Corticosteroids and Plasmapheresis (P7-1.008)

SE Thompson; Gabriela Bou; James Greene; Spencer Hutto

doi:10.1212/wnl.0000000000216504

June 9, 2026Neurology

Rescue Tocilizumab in MOGAD Optic Neuritis Refractory to Corticosteroids and Plasmapheresis (P7-1.008)

View Full Paper

Ask AI

Bookmark

Share

Key Points

To report on the effectiveness of tocilizumab in treating MOGAD optic neuritis unresponsive to standard therapies.
Described a single case of a patient with MOGAD optic neuritis
Treatment involved acute and long-term tocilizumab administration
Previous treatments included corticosteroids and plasmapheresis.
Substantial visual improvement observed after tocilizumab treatment
Patient had profound visual impairment prior to intervention
Tocilizumab provided relief where corticosteroids and plasmapheresis failed.

Implication

Case report shows visual improvement in MOGAD optic neuritis after tocilizumab treatment, suggesting its efficacy.

Abstract

To report a case of profound visual impairment due to MOGAD optic neuritis refractory to corticosteroids and plasmapheresis, but responsive to acute and long-term treatment with tocilizumab.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Thompson et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3d6faef96ed7f056452 https://doi.org/10.1212/wnl.0000000000216504

View Full Paper

Ask AI

Bookmark

Share

Rescue Tocilizumab in MOGAD Optic Neuritis Refractory to Corticosteroids and Plasmapheresis (P7-1.008)

Key Points

Implication

Abstract

Discussion

Cite This Study

Rescue Tocilizumab in MOGAD Optic Neuritis Refractory to Corticosteroids and Plasmapheresis (P7-1.008)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading